A Multifactorial Approach to Reduce Cardiovascular Disease in Type 2 Diabetes Mellitus: Now More Than Ever

Hospital Practice
Jan N Basile

Abstract

Managing cardiovascular (CV) risk is an important part of caring for patients with type 2 diabetes mellitus, as the disease itself confers CV risk. Many CV risk factors (such as hypertension, dyslipidemia, and obesity) have been found to be more common among individuals with diabetes than in the general population. A growing body of evidence provides guidance for clinicians on how to balance control of hyperglycemia with management of these risk factors. Newer classes of antihyperglycemic agents have been associated with beneficial effects on several CV risk factors; several studies evaluating the effect of these newer diabetic medications on CV outcomes have been published, and several more are in progress. While evidence continues to unfold about the benefits of risk factor control in patients with type 1 diabetes mellitus, this article reviews evidence related to risk-factor control in patients with type 2 diabetes mellitus as well as recent findings on the effect of newer drug classes on CV risk factors and outcomes. Favorably altering CV risk factors appears to improve outcomes, and is more important now than ever before.

References

Nov 21, 2002·JAMA : the Journal of the American Medical Association·Jackson T WrightUNKNOWN African American Study of Kidney Disease and Hypertension Study Group
Dec 20, 2002·JAMA : the Journal of the American Medical Association·UNKNOWN ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatm
Jan 31, 2003·The New England Journal of Medicine·Peter GaedeOluf Pedersen
Jun 30, 2004·Diabetes & Metabolism·P M NilssonUNKNOWN Steering Committee of the Swedish National Diabetes Register
Oct 1, 2005·Inhalation Toxicology·H Daniel RothXiao Liu
Jul 26, 2006·Hypertension·Frans H H LeenenUNKNOWN Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group
Feb 8, 2008·The New England Journal of Medicine·Peter GaedeOluf Pedersen
Feb 8, 2008·The New England Journal of Medicine·Mayank B Patel, Ashok Bhalla
Feb 19, 2008·Journal of the American College of Cardiology·Michael MillerUNKNOWN PROVE IT-TIMI 22 Investigators
Jun 10, 2008·The New England Journal of Medicine·UNKNOWN Action to Control Cardiovascular Risk in Diabetes Study GroupWilliam T Friedewald
Sep 12, 2008·The New England Journal of Medicine·Rury R HolmanH Andrew W Neil
Dec 19, 2008·The New England Journal of Medicine·William DuckworthUNKNOWN VADT Investigators
Feb 21, 2009·Nature Clinical Practice. Endocrinology & Metabolism·Arshag D Mooradian
Aug 6, 2009·Diabetologia·UNKNOWN Control GroupM Woodward
Aug 18, 2009·Lancet·John S Yudkin, Bernd Richter
Mar 17, 2010·The New England Journal of Medicine·William C CushmanFaramarz Ismail-Beigi
Jan 14, 2011·Diabetes, Obesity & Metabolism·A J TremblayP Couture
Apr 15, 2011·Metabolism: Clinical and Experimental·Christina VoulgariNicholas Tentolouris
Oct 1, 2011·Diabetes, Obesity & Metabolism·R A DeFronzoS Del Prato
Jun 13, 2012·The New England Journal of Medicine·Hertzel C GersteinSalim Yusuf
Jan 8, 2013·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Thomas ForstAxel Haupt
Jun 26, 2013·The New England Journal of Medicine·Rena R WingSusan Z Yanovski

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.